GlassScriptPhysician profile
Daniel Nievesquinones
NPI 1194714634
$39,831.83
in general payments reported to CMS, 2019-2025
81 companies · $5,001 in 2025
The $5,001 reported for 2025 was more than what 97% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,456 · 2020: $11K · 2021: $7,837 · 2022: $3,104 · 2023: $3,369 · 2024: $4,924 · 2025: $5,001.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Education: $27.33.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,266.28 |
| Education | $27.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $10,071.96 | 2019-2022 | |
| Abbvie INC. | $5,230.00 | 2020-2025 | |
| Biogen, INC. | $1,652.96 | 2019-2025 | Vumerity, Tysabri, Avonex |
| Neurocrine Biosciences, INC. | $1,479.90 | 2020-2025 | Ingrezza |
| Livanova USA, INC. | $1,385.04 | 2019-2024 | Vns Therapy Sentiva Model 1000 Generator |
| Ucb, INC. | $1,150.55 | 2019-2025 | Nayzilam, Rystiggo, Briviact |
| Genzyme Corporation | $1,015.51 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $1,009.03 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Banner Life Sciences, LLC | $1,008.54 | 2021-2023 | |
| Emd Serono, INC. | $957.18 | 2019-2025 | Mavenclad |
| Lilly USA, LLC | $911.75 | 2019-2025 | Amyvid, Emgality, Kisunla |
| Lundbeck LLC | $901.29 | 2019-2025 | Vyepti, Rexulti |
| Novartis Pharmaceuticals Corporation | $880.89 | 2020-2025 | |
| Argenx US, INC. | $748.66 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Alexion Pharmaceuticals, INC. | $719.72 | 2019-2025 | Ultomiris |
Show all 81 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Nievesquinones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.